AR050297A1 - Hidantoinas sustituidas - Google Patents
Hidantoinas sustituidasInfo
- Publication number
- AR050297A1 AR050297A1 ARP050103440A ARP050103440A AR050297A1 AR 050297 A1 AR050297 A1 AR 050297A1 AR P050103440 A ARP050103440 A AR P050103440A AR P050103440 A ARP050103440 A AR P050103440A AR 050297 A1 AR050297 A1 AR 050297A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- substituted
- alkyl
- alkoxy
- compounds
- Prior art date
Links
- 150000001469 hydantoins Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Los compuestos de la presente son utiles para tratar enfermedades caracterizadas por la hiperactividad de la MEK. Por consiguiente, los compuestos son utiles para el tratamiento de enfermedades, tales como el cáncer, trastornos cognitivos y del SNC y enfermedades inflamatorias/autoinmunes. Reivindicacion 1: Un compuesto de la formula (1) en la que: R1 se elige entre el conjunto formado por un grupo arilo sustituido o sin sustituir y un grupo heteroarilo sustituido o sin sustituir; R2 es H; R3 es un grupo alquilo; R4 se elige entre el grupo formado por un grupo arilo sustituido o sin sustituir, hidroxilo, alcoxi, alcoxi sustituido y un grupo heteroarilo o alquilo sustituido o sin sustituir; R5 se elige entre el grupo formado por COOR, COR, CON(R7)2, CHOHR y S(O)nR, en los que n es 0-2 y en los que R es alquilo o alquilo sustituido por un grupo alcoxi; y R6 y R7 se eligen entre H y un grupo alquilo, opcionalmente en forma de sus racematos, sus enantiomeros, sus diastereoisomeros o mezclas de los mismos, o las sales, ésteres o profármacos farmacéuticamente aceptables del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60217504P | 2004-08-17 | 2004-08-17 | |
| US68299705P | 2005-05-20 | 2005-05-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR050297A1 true AR050297A1 (es) | 2006-10-11 |
Family
ID=35589619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050103440A AR050297A1 (es) | 2004-08-17 | 2005-08-16 | Hidantoinas sustituidas |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7427635B2 (es) |
| EP (1) | EP1781649B1 (es) |
| JP (1) | JP4927733B2 (es) |
| KR (2) | KR100889721B1 (es) |
| AR (1) | AR050297A1 (es) |
| AT (1) | ATE404556T1 (es) |
| AU (1) | AU2005274390B2 (es) |
| BR (1) | BRPI0514515A (es) |
| CA (1) | CA2576599A1 (es) |
| DE (1) | DE602005008986D1 (es) |
| ES (1) | ES2313389T3 (es) |
| MX (1) | MX2007001846A (es) |
| PL (1) | PL1781649T3 (es) |
| RU (1) | RU2383542C2 (es) |
| TW (1) | TW200621764A (es) |
| WO (1) | WO2006018188A2 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200621766A (en) * | 2004-09-17 | 2006-07-01 | Hoffmann La Roche | Substituted hydantoins |
| US7612212B2 (en) * | 2006-02-22 | 2009-11-03 | Hoffmann-La Roche Inc. | Substituted hydantoins |
| CN101702878B (zh) * | 2007-05-11 | 2012-11-28 | 弗·哈夫曼-拉罗切有限公司 | 可溶性差的药物的药物组合物 |
| CN101778839A (zh) * | 2007-08-16 | 2010-07-14 | 霍夫曼-拉罗奇有限公司 | 取代的乙内酰脲 |
| WO2009080523A1 (en) | 2007-12-20 | 2009-07-02 | F. Hoffmann-La Roche Ag | Substituted hydantoins as mek kinase inhibitors |
| US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
| US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
| US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| JP5507552B2 (ja) | 2008-06-16 | 2014-05-28 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 癌を処置するための化合物 |
| EP2370568B1 (en) | 2008-12-10 | 2017-07-19 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
| TW201113280A (en) * | 2009-07-03 | 2011-04-16 | Nensius Res As | Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the CNS |
| RU2571930C2 (ru) | 2010-02-25 | 2015-12-27 | Дана-Фарбер Кэнсер Инститьют, Инк. | Мутации braf, обеспечивающие резистентность к ингибиторам braf |
| JP5879273B2 (ja) | 2010-03-01 | 2016-03-08 | ジーティーエックス・インコーポレイテッド | 癌を処置するための化合物 |
| US20130059851A1 (en) | 2010-03-09 | 2013-03-07 | Dana-Farber Cancer Institute, Inc. | Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy |
| WO2011134969A1 (de) | 2010-04-28 | 2011-11-03 | Bayer Cropscience Ag | Ketoheteroarylpiperidin und -piperazin derivate als fungizide |
| WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| EA202190558A1 (ru) | 2018-09-17 | 2022-02-03 | Янгчжин Фарм. Ко., Лтд. | Новые производные тиазола и их фармацевтически приемлемые соли |
| KR20210116325A (ko) * | 2020-03-13 | 2021-09-27 | 영진약품 주식회사 | 티아졸 유도체 또는 이의 약제학적으로 허용가능한 염을 포함하는 암의 예방 또는 치료용 약학 조성물 |
| KR102335637B1 (ko) * | 2020-03-13 | 2021-12-06 | 영진약품 주식회사 | 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염 |
| KR20210146144A (ko) | 2020-05-26 | 2021-12-03 | 엘지전자 주식회사 | 카트부 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5770573A (en) * | 1993-12-06 | 1998-06-23 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| KR20010014362A (ko) | 1997-07-01 | 2001-02-26 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 4-브로모 또는 4-요오도 페닐아미노 벤즈히드록삼산유도체 및 ｍｅｋ 억제제로서의 그의 용도 |
| AU2001252270B2 (en) * | 2000-05-03 | 2005-12-15 | F. Hoffmann-La Roche Ag | Hydantoin-containing glucokinase activators |
| PT1406899E (pt) * | 2001-07-19 | 2007-01-31 | Pfizer Italia Srl | Derivados de fenilacetamido-tiazole, processo para a sua preparação e a sua utilização como agentes antitumorais |
-
2005
- 2005-08-09 ES ES05771890T patent/ES2313389T3/es not_active Expired - Lifetime
- 2005-08-09 DE DE602005008986T patent/DE602005008986D1/de not_active Expired - Lifetime
- 2005-08-09 CA CA002576599A patent/CA2576599A1/en not_active Abandoned
- 2005-08-09 PL PL05771890T patent/PL1781649T3/pl unknown
- 2005-08-09 JP JP2007526351A patent/JP4927733B2/ja not_active Expired - Fee Related
- 2005-08-09 AU AU2005274390A patent/AU2005274390B2/en not_active Ceased
- 2005-08-09 KR KR1020077004075A patent/KR100889721B1/ko not_active Expired - Fee Related
- 2005-08-09 BR BRPI0514515-5A patent/BRPI0514515A/pt not_active IP Right Cessation
- 2005-08-09 RU RU2007109651/04A patent/RU2383542C2/ru not_active IP Right Cessation
- 2005-08-09 KR KR1020087032084A patent/KR20090006885A/ko not_active Ceased
- 2005-08-09 MX MX2007001846A patent/MX2007001846A/es active IP Right Grant
- 2005-08-09 WO PCT/EP2005/008633 patent/WO2006018188A2/en not_active Ceased
- 2005-08-09 EP EP05771890A patent/EP1781649B1/en not_active Expired - Lifetime
- 2005-08-09 AT AT05771890T patent/ATE404556T1/de active
- 2005-08-11 US US11/202,299 patent/US7427635B2/en not_active Expired - Fee Related
- 2005-08-15 TW TW094127672A patent/TW200621764A/zh unknown
- 2005-08-16 AR ARP050103440A patent/AR050297A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008509950A (ja) | 2008-04-03 |
| RU2383542C2 (ru) | 2010-03-10 |
| EP1781649A2 (en) | 2007-05-09 |
| MX2007001846A (es) | 2007-03-28 |
| CA2576599A1 (en) | 2006-02-23 |
| KR20090006885A (ko) | 2009-01-15 |
| DE602005008986D1 (de) | 2008-09-25 |
| RU2007109651A (ru) | 2008-09-27 |
| BRPI0514515A (pt) | 2008-06-10 |
| WO2006018188A2 (en) | 2006-02-23 |
| AU2005274390A1 (en) | 2006-02-23 |
| ES2313389T3 (es) | 2009-03-01 |
| US7427635B2 (en) | 2008-09-23 |
| US20060041146A1 (en) | 2006-02-23 |
| PL1781649T3 (pl) | 2009-01-30 |
| TW200621764A (en) | 2006-07-01 |
| AU2005274390B2 (en) | 2012-01-19 |
| KR100889721B1 (ko) | 2009-03-23 |
| WO2006018188A3 (en) | 2006-05-18 |
| JP4927733B2 (ja) | 2012-05-09 |
| EP1781649B1 (en) | 2008-08-13 |
| ATE404556T1 (de) | 2008-08-15 |
| KR20070034635A (ko) | 2007-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR050297A1 (es) | Hidantoinas sustituidas | |
| AR051290A1 (es) | Derivados de hidantoina sustituidas | |
| UY38767A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados con braf | |
| AR046186A1 (es) | Compuestos derivados de 1,3,8-triaza-espiro[4.5]decan-4-ona | |
| AR062387A2 (es) | El uso de un compuesto derivado de imidazo[1,2-a] piridina, y un medicamento que lo contiene | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| CU20090184A7 (es) | Compuestos amino-heterocíclicos | |
| PE20180030A1 (es) | Compuestos biciclicos de sulfonamida cetona | |
| EA200501658A2 (ru) | Производные азаспироалканов в качестве ингибиторов металлопротеаз | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| CL2010001486A1 (es) | Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento de enfermedades tales como cancer, diabetes, enfermedad de alzheimer, enfermedad hepatica, trastornos del snc, entre otras. | |
| AR044402A1 (es) | Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen. | |
| SE0202134D0 (sv) | Therapeutic agents | |
| AR059590A1 (es) | Inhibidores de quinasa basados en la hidantoina | |
| AR070520A1 (es) | Derivados de azuleno nitrogenados,composiciones farmaceuticas que los contienen,proceso de preparacion y usos de los mismos para tratar trastornos metabolicos y digestivos,entre otros. | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| UY28333A1 (es) | Inhibidores de caspasa y sus usos. | |
| CR6165A (es) | Procedimientos e intermedios para preparar compuestos anticancerosos | |
| AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
| AR058379A1 (es) | Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas. | |
| AR048789A1 (es) | Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar) | |
| PE20190964A1 (es) | Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica | |
| PE20181853A1 (es) | 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4h-pirazolo[4,3-c]piridin-4-onas como inhibidores de pde1 | |
| PA8609801A1 (es) | Compuestos para el tratamiento de transtornos neurogenerativos | |
| AR070910A1 (es) | Derivados de sulfonamida sustituida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |